Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute (NCI) is announcing a limited competition Notice of Funding Opportunity aimed at supporting the continuation of two key biospecimen banking resources: the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). The NCTN Biobanks serve the NCI-funded NCTN and Community Oncology Research Program (NCORP), facilitating the collection, processing, storage, and distribution of high-quality human biospecimens from thousands of patients enrolled in cancer clinical trials annually. These biobanks focus on supporting translational research through biomarker development, validation, and broader scientific studies related to cancer treatment, prevention, and control. They operate in concert with large multi-site clinical trials to provide clinically annotated specimens, enabling investigation into disease mechanisms, therapeutic responses, and clinical outcomes. The EET Biobank addresses the biospecimen needs of the Experimental Therapeutics Clinical Trials Network (ETCTN) and other early-phase, experimental clinical trials involving investigational new drugs. Unlike the NCTN Biobanks, the EET Biobank bridges basic science with clinical application, supporting biomarker assay development, pharmacokinetic and pharmacodynamic studies, and investigations into drug resistance and patient stratification. This resource is critical for accelerating the development of effective cancer treatments through NCI's IND efforts. Although applications are not currently being accepted, this forecast notification allows potential applicants ample time to establish collaborations and develop responsive projects. All submitted applications will undergo peer review and funding will be awarded based on merit.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources:
- The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and
- The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials.
The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. NCTN Biobanks support the biobanking operations of the NCTN funded through the Cancer Therapy Evaluation Program (CTEP) and NCORP funded through the Division of Cancer Prevention (DCP). The clinical trials conducted through NCTN and NCORP enroll thousands of patients with adult and childhood cancers each year. NCTN Biobank operations aim to facilitate hypothesis-driven biomarker development and validation, secondary research studies, and broader scientific discovery. Biospecimens collected through harmonized protocols and long-term follow-up across large multi-site clinical trials provide valuable resources for studying disease mechanisms, therapeutic response, and clinical outcomes in different types of cancers.
This NOFO will also support the continuation of the EET Biobank, a dedicated resource with a primary focus on meeting the biospecimen banking needs of the ETCTN and other early-phase and experimental clinical trials involving investigational new drugs (INDs). Biospecimens collected from the early phase clinical trials enable validated biomarker assay development, pharmacokinetic and pharmacodynamic studies, investigation of drug action and resistance mechanisms, improved patient stratification, and broader scientific discovery. Unlike the NCTN Biobank, the EET Biobank bridges basic science and clinical applications that enable acceleration of NCI’s IND development efforts for effective cancer treatments. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.